Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Daiichi Sankyo Ltd (OP:DSKYF)

20.50 +0.50 (+2.50%)

Streaming Delayed Price Updated: 2:38 PM EST, Jan 28, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	11,594
Open	17.86
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	20.00
Today's Range	17.86 - 20.50
52wk Range	18.96 - 30.60
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape

January 26, 2026

As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the...

Via Finterra

FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer ↗

June 24, 2025

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due.

Via Benzinga

Performance

YTD	-6.8%	-6.8%
1 Month	-6.4%	-6.4%
3 Month	-21.6%	-21.6%
6 Month	-21.4%	-21.4%
1 Year	-28.1%	-28.1%

More News

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients ↗

April 21, 2025

Via Benzinga

Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact ↗

March 20, 2023

Via Benzinga

Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine ↗

January 13, 2023

Via Benzinga

FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients ↗

January 28, 2025

Via Benzinga

FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients ↗

January 21, 2025

Via Benzinga

After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer ↗

December 06, 2024

Via Benzinga

Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients ↗

September 23, 2024

Via Benzinga

AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial ↗

September 10, 2024

Via Benzinga

Week In Review: Curon Out-Licenses T-Cell-Engager To Merck For $700 Million Upfront ↗

August 10, 2024

Via Talk Markets

Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10 ↗

August 07, 2024

Via Benzinga

Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast ↗

July 30, 2024

Via Benzinga

FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug ↗

June 27, 2024

Via Benzinga

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More ↗

June 24, 2024

Via Benzinga

Why Is AstraZeneca Stock Trading Lower On Tuesday? ↗

May 28, 2024

Via Benzinga

Double Good News For AstraZeneca's Breast Cancer Drugs ↗

April 29, 2024

Via Benzinga

AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor ↗

April 08, 2024

Via Benzinga

What's Going On With Pfizer Stock Today? ↗

January 25, 2024

Via Benzinga

Merck Signs Multi-Billion Deal With Japan's Daiichi Sankyo For Cancer Therapy Drug Development ↗

October 20, 2023

Via Benzinga

Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting ↗

September 22, 2023

Via Benzinga

AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials ↗

September 11, 2023

Via Benzinga

FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt ↗

July 21, 2023

Via Benzinga

AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial ↗

July 03, 2023

Via Benzinga

AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting ↗

March 06, 2023

Via Benzinga

Frequently Asked Questions

Is Daiichi Sankyo Ltd publicly traded?

Yes, Daiichi Sankyo Ltd is publicly traded.

What exchange does Daiichi Sankyo Ltd trade on?

Daiichi Sankyo Ltd trades on the OTC Traded

What is the ticker symbol for Daiichi Sankyo Ltd?

The ticker symbol for Daiichi Sankyo Ltd is DSKYF on the OTC Traded

What is the current price of Daiichi Sankyo Ltd?

The current price of Daiichi Sankyo Ltd is 20.50

When was Daiichi Sankyo Ltd last traded?

The last trade of Daiichi Sankyo Ltd was at 01/28/26 02:38 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.